Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in Sanfilippo Syndrome
NCT06333041Phase 3Recruiting
- Sponsor
- The Lundquist Institute
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Sanfilippo syndrome (2 arms), sponsored by The Lundquist Institute. Primary endpoint: Sanfilippo Behavior Rating Scale - mood/anger/aggression score at 16 weeks. Started Apr 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Sanfilippo syndrome
Beyond the preview
Go deeper on NCT06333041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06333041.